Seminars in Nephrology
Volume 28, Issue 3 , Pages 245-251, May 2008

Vasopressin Receptor Mutations in Nephrogenic Diabetes Insipidus

  • Daniel G. Bichet, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Daniel G. Bichet, MD, Research Centre, Hôpital du Sacré-Coeur de Montréal, 5400 Boulevard Gouin West, Montréal, Québec H4J 1C5, Canada.

Genetics of Renal Diseases, Groupe d'Étude des Protéines, Membranaires, Montréal, Québec, Canada. Department of Medicine and Physiology, Université de Montréal, Research Centre, Montréal, Québec, Canada. Nephrology Service, Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada.

Summary 

The purpose of this review is first to describe the importance of early detection of vasopressin receptor mutations responsible for X-linked nephrogenic diabetes insipidus (NDI). We have proposed that all families with hereditary diabetes insipidus should have their molecular defect identified because early diagnosis and treatment of affected infants can avert the physical and mental retardation that results from repeated episodes of dehydration. Secondly, 95 published missense mutations responsible for X-linked NDI are likely to result in misfolded arginine-vasopressin V2 receptors that are trapped in the endoplasmic reticulum. These misfolded receptors are unable to reach the plasma membrane in principal collecting duct cells and to engage the circulating antidiuretic hormone, arginine-vasopressin. These misfolded proteins potentially could be rescued with pharmacologic chaperones, an active area of research pertinent to other hereditary protein misfolding diseases such as cystic fibrosis, phenylketonuria, and Anderson-Fabry disease among many others. Finally, a long-term careful surveillance of all patients with hereditary NDI should be performed to prevent chronic renal failure likely caused by the long-term functional tract obstruction with reflux.

Keywords: Nephrogenic diabetes insipidus, AVPR2 mutations, mutational analysis, misfolded mutants, pharmacological chaperones

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by the Canadian Institutes of Health Research, and by the Kidney Foundation of Canada. Dr. Bichet holds a Canada Research Chair in Genetics of Renal Diseases.

PII: S0270-9295(08)00048-X

doi:10.1016/j.semnephrol.2008.03.005

Seminars in Nephrology
Volume 28, Issue 3 , Pages 245-251, May 2008